PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8230547-0 1993 Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. Cisplatin 34-43 chromobox 8 Homo sapiens 89-93 27524236-5 2016 In this study, we used MTS assay to examine cell viabilities of PC-3, LNCaP, DU-145 and RM-1 cells after treated by HT and cisplatin. Cisplatin 123-132 chromobox 8 Homo sapiens 64-68 27524236-6 2016 Then colony formation of PC-3 and DU-145 cells after treated with HT and cisplatin were photographed. Cisplatin 73-82 chromobox 8 Homo sapiens 25-29 24179545-5 2013 The sensitivity of the PC3 cells to docetaxel and cisplatin was significantly enhanced following treatment with AexU, resulting in a decrease in the IC50 of the two agents by ~90%. Cisplatin 50-59 chromobox 8 Homo sapiens 23-26 21682664-7 2011 Consistent with these findings, the NOX activity induced by cisplatin was higher in LNCaP cells than in PC3 and DU145 cells. Cisplatin 60-69 chromobox 8 Homo sapiens 104-107 20209498-3 2011 In particular, [AuCl(2) (DMDT)] was proved cytotoxic against cisplatin-resistant R-PC3 cells, with activity levels comparable to those induced on the parent cisplatin-sensitive PC3 cells, ruling out the occurrence of cross-resistance phenomena. Cisplatin 61-70 chromobox 8 Homo sapiens 83-86 20209498-3 2011 In particular, [AuCl(2) (DMDT)] was proved cytotoxic against cisplatin-resistant R-PC3 cells, with activity levels comparable to those induced on the parent cisplatin-sensitive PC3 cells, ruling out the occurrence of cross-resistance phenomena. Cisplatin 157-166 chromobox 8 Homo sapiens 177-180 20813451-5 2010 Overexpression of Kindlin-2 in LNCaP protected the cells from cisplatin-induced death, while Kindlin-2 knock-down in PC-3 cells enhanced cisplatin sensitivity. Cisplatin 137-146 chromobox 8 Homo sapiens 117-121 19209173-3 2009 The combination of phenoxodiol and cisplatin was synergistic in DU145, and additive in PC3, as assessed by the Chou-Talalay method. Cisplatin 35-44 chromobox 8 Homo sapiens 87-90 26993079-3 2016 The complex is highly cytotoxic in the low muM range and is as potent as the clinical drug cisplatin against the human cancer cell lines A2780, A549, HCT116, and PC3. Cisplatin 91-100 chromobox 8 Homo sapiens 162-165 21448923-5 2011 Here, we report that both chemotherapeutic drugs (cisplatin) and proteasome inhibitors induced caspase-3-associated cell death in parental PC-3 cells whereas non-caspase-3 associated cell death in PC3-AR cells. Cisplatin 50-59 chromobox 8 Homo sapiens 197-200 16327999-2 2006 At a cisplatin concentration of 20 microM, 22RV1 and DU-145 cells showed approximately 22% and 18% and PC-3 and LNCaP cells showed approximately 4 and 10% dead cells, respectively. Cisplatin 5-14 chromobox 8 Homo sapiens 103-107 16327999-4 2006 DU-145 and 22RV1 cells showed apoptosis induction at 5- and 2-microM cisplatin, whereas in the case of LNCaP and PC-3 cells comparable apoptosis induction was observed at 100-microM cisplatin; hence, the difference between the two groups of cell lines with respect to apoptosis induction is 20- and 50-fold, respectively. Cisplatin 182-191 chromobox 8 Homo sapiens 113-117 7992463-8 1994 Cisplatin increased S-phase in both cell lines, increasing PCNA expression in PC-3 and decreasing it in DU-145 cells. Cisplatin 0-9 chromobox 8 Homo sapiens 78-82 8230547-1 1993 We have isolated cis-diamminedichloroplatinum (II) (CDDP)-resistant variants, P/CDP4 and P/CDP5, from human prostatic cancer PC-3 cells after a stepwise exposure to CDDP. Cisplatin 17-50 chromobox 8 Homo sapiens 125-129 8230547-1 1993 We have isolated cis-diamminedichloroplatinum (II) (CDDP)-resistant variants, P/CDP4 and P/CDP5, from human prostatic cancer PC-3 cells after a stepwise exposure to CDDP. Cisplatin 52-56 chromobox 8 Homo sapiens 125-129 8230547-5 1993 Flameless atomic absorption spectrophotometry revealed that intracellular accumulation of CDDP in P/CDP4 and P/CDP5 was decreased to 18 to 34% and 9 to 18% of that of PC-3, respectively, when PC-3 and its CDDP-resistant counterparts were incubated with 5 and 10 micrograms./ml. Cisplatin 90-94 chromobox 8 Homo sapiens 167-171 8230547-5 1993 Flameless atomic absorption spectrophotometry revealed that intracellular accumulation of CDDP in P/CDP4 and P/CDP5 was decreased to 18 to 34% and 9 to 18% of that of PC-3, respectively, when PC-3 and its CDDP-resistant counterparts were incubated with 5 and 10 micrograms./ml. Cisplatin 90-94 chromobox 8 Homo sapiens 192-196 8230547-7 1993 These data suggest that decreased drug accumulation is involved in the development of CDDP-resistance in the PC-3 cell line. Cisplatin 86-90 chromobox 8 Homo sapiens 109-113 7693335-3 1993 In experiments of combination therapy with chemotherapeutic agents, the combination of TNP-470 (100 mg/kg) and cisplatin (5 mg/kg) showed an additive antitumor effect (from treated versus control, 38 and 22% to 5%) against PC-3 carcinoma. Cisplatin 111-120 chromobox 8 Homo sapiens 223-227 34334870-5 2021 These complexes showed higher cytotoxicity than cisplatin against a wide variety of cancer cell lines such as K-562 (leukemia), HOP-92 (lung), HCT-116 (colon), OVCAR-8 (ovarian), PC-3 (prostate), MDA-MB-468 (breast), and melanoma cancer cell lines. Cisplatin 48-57 chromobox 8 Homo sapiens 179-183